The stock of Summit Therapeutics Inc (SMMT) has seen a -7.11% decrease in the past week, with a -1.73% drop in the past month, and a 3.24% flourish in the past quarter. The volatility ratio for the week is 6.73%, and the volatility levels for the past 30 days are at 6.67% for SMMT. The simple moving average for the last 20 days is -4.03% for SMMT stock, with a simple moving average of 9.12% for the last 200 days.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
Additionally, the 36-month beta value for SMMT is -0.46. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SMMT is 115.12M and currently, short sellers hold a 18.43% ratio of that float. The average trading volume of SMMT on April 02, 2025 was 2.45M shares.
SMMT) stock’s latest price update
Summit Therapeutics Inc (NASDAQ: SMMT)’s stock price has plunge by -2.54relation to previous closing price of 19.29. Nevertheless, the company has seen a -7.11% plunge in its stock price over the last five trading sessions. fool.com reported 2025-03-31 that Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%, respectively, as of 12:55 p.m. ET.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Citigroup repeating the rating for SMMT by listing it as a “Buy.” The predicted price for SMMT in the upcoming period, according to Citigroup is $35 based on the research report published on March 26, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to SMMT, setting the target price at $30 in the report published on March 12th of the current year.
SMMT Trading at -8.14% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.53% of loss for the given period.
Volatility was left at 6.67%, however, over the last 30 days, the volatility rate increased by 6.73%, as shares sank -1.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.21% lower at present.
During the last 5 trading sessions, SMMT fell by -7.11%, which changed the moving average for the period of 200-days by +127.88% in comparison to the 20-day moving average, which settled at $19.59. In addition, Summit Therapeutics Inc saw 5.35% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SMMT
The total capital return value is set at -0.54. Equity return is now at value -94.89, with -69.32 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -19.69. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -24.28.
Currently, EBITDA for the company is 0.31 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.15.
Conclusion
In conclusion, Summit Therapeutics Inc (SMMT) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
